Exploring the two-gene ratio in breast cancer-independent roles for HOXB13 and IL17BR in prediction of clinical outcome

Breast Cancer Research and Treatment

Volumn 107, Issue 2, 2008, Pages 225-234

  Jerevall, Piiha Lotta ^a   Brommesson, Sara ^b   Strand, Carina ^b   Gruvberger Saal, Sofia ^b   Malmström, Per ^b   Nordenskjöld, Bo ^a   Wingren, Sten ^a   Söderkvist, Peter ^a   Fernö, Mårten ^b   Stål, Olle ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; HOMEOBOX B13 PROTEIN; HOMEODOMAIN PROTEIN; INTERLEUKIN 17B RECEPTOR; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; GENETICS; HOMEOBOX B13 GENE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; INTERLEUKIN 17B RECEPTOR GENE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; RISK ASSESSMENT;

BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, INTERLEUKIN; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAMOXIFEN; TREATMENT OUTCOME;

EID: 37249009630     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9541-8     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717
2. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874
3. Gruvberger S, Ringner M, Chen Y et al (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61(16):5979-5984
4. Sotiriou C, Neo SY, McShane LM et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100(18):10393-10398
5. van 't Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530-536
6. Wang Y, Klijn JG, Zhang Y et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671-679
7. van de Vijver MJ, He YD, van 't Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999-2009
8. Jansen MP, Foekens JA, van Staveren IL et al (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23(4):732-740
9. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817-2826
10. Ma XJ, Wang Z, Ryan PD et al (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5(6):607-616
11. Reid JF, Lusa L, De Cecco L et al (2005) Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 97(12):927-930
12. Goetz MP, Suman VJ, Ingle JN et al (2006) A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 12(7 Pt 1):2080-2087
13. Ma XJ, Hilsenbeck SG, Wang W et al (2006) The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24(28):4611-4619
14. Swedish Breast Cancer Cooperative Group (1996) Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88(21):1543-1549
15. Ryden L, Jonsson PE, Chebil G, et al (2005) Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 41(2):256-264
16. Fernö M, Stål O, Baldetorp B et al (2000) Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res Treat 59(1):69-76
17. Stål O, Borg Å, Fernö M et al (2000) ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 11(12):1545-1550
18. Edwards S, Campbell C, Flohr P, et al (2005) Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. Br J Cancer 92(2):376-381
19. Zhao Y, Yamashita T, Ishikawa M (2005) Regulation of tumor invasion by HOXB13 gene overexpressed in human endometrial cancer. Oncol Rep 13(4):721-726
20. Lopez R, Garrido E, Pina P et al (2006) HOXB homeobox gene expression in cervical carcinoma. Int J Gynecol Cancer 16(1):329-335
21. Okuda H, Toyota M, Ishida W, et al (2006) Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene 25(12):1733-1742
22. Jung C, Kim RS, Zhang H et al (2005) HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation. Br J Cancer 92(12):2233-2239
23. Maeda K, Hamada J, Takahashi Y, et al (2005) Altered expressions of HOX genes in human cutaneous malignant melanoma. Int J Cancer 114(3):436-441
24. Jung C, Kim RS, Lee SJ et al (2004) HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. Cancer Res 64(9):3046-3051
25. Jung C, Kim RS, Zhang HJ et al (2004) HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res 64(24):9185-9192
26. Rodriguez BAT, Jin VX, Cheng AS, et al (2006) HOXB13 is an estrogen receptor responsive gene preferentially methylated in ER-positive breast cancer. In: Proceedings of the 97th annual meeting, AACR, Washington, USA, 1-5 April 2006
27. Cantile M, Pettinato G, Procino A, et al (2003) In vivo expression of the whole HOX gene network in human breast cancer. Eur J Cancer 39(2):257-264
28. Apiou F, Flagiello D, Cillo C, et al (1996) Fine mapping of human HOX gene clusters. Cytogenet Cell Genet 73(1-2):114-115
29. Shi Y, Ullrich SJ, Zhang J, et al (2000) A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem 275(25):19167-19176
30. Lee J, Ho WH, Maruoka M, et al (2001) IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem 276(2):1660-1664